NASDAQ •
Healthcare •
Biotechnology •
Quote as of 05/04/2026 16:00
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization48,965 mln
Float61.98 mln
Earnings Date05/07/2026
EPS
19.59
Stretched
P / E
41.40
High premium
Piotroski F-Score
4
/ 9
Borderline
Beneish M-Score
-1.71
Likely manipulated
1-Year Forecast
1,036
Strong upside
Relative Strength
29
/ 100
Underperforming
Business Description
argenx SE is a Netherlands-based biopharmaceutical company focused on treating autoimmune diseases, operating across the United States, Japan, China, and other markets worldwide. Its two approved medicines, VYVGART and VYVGART HYTRULO, are used to treat several serious immune conditions, including generalized myasthenia gravis, immune thrombocytopenia, and chronic inflammatory demyelinating polyneuropathy. The company is also advancing a broad pipeline of experimental treatments targeting a range of additional autoimmune and inflammatory diseases. Founded in 2008 and headquartered in Amsterdam, argenx works with partners such as Zai Lab, Halozyme, and AbbVie to develop and bring its therapies to patients.
